Cell Surface Marker for Detection of Activated B Cells involved in Disease

Tech ID: 23028 / UC Case 2012-349-0


Proteins expressed in the membrane of B cells represent compelling targets for therapeutic monoclonal antibody development. Although drugs are commercially available, for example, Rituxan®, which targets CD20, a cell surface protein present in all B cells, there is currently no therapy that selectively acts on activated B lymphocytes.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20160237152 08/08/2016 2012-349

Technology Description

Researchers at the University of California, Irvine, have discovered a novel marker expressed in activated B cells that can be selectively targeted, for example, using monoclonal antibody therapy.


The present invention provides a novel strategy for selectively targeting or detecting activated B cells in the presence of normal B cells without harming the latter. This innovative research can be exploited in detecting and treating human diseases where activated B cells are involved, e.g., leukemia, autoimmune disease (i.e., lupus, rheumatoid arthritis, etc...), etc...


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


Marker, Biomarker, activated B cells, leukemia, autoimmune disease, Antibodies

Categorized As

  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2013 - 2016, The Regents of the University of California
Terms of use | Privacy Notice